CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.
Overview
Deciding between CRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals (NASDAQ:VRTX) involves weighing high-growth gene-editing potential against a profitable, established leader. Both companies currently partner on breakthrough therapies but offer different investor profiles.
CRISPR Therapeutics focuses on transformative gene-based medicines, while Vertex dominates the cystic fibrosis market and generates substantial cash flow. They share the profits of their joint gene-editing therapy, CASGEVY. This comparison evaluates their financial health, risk factors, and current valuations to help you decide which fits your portfolio strategy better.
Details
CRISPR Therapeutics AG focuses on creating transformative medicines through its proprietary gene-editing platform. Its flagship product is CASGEVY, a therapy developed for sickle cell disease and transfusion-dependent beta thalassemia. The company relies heavily on its partnership with Vertex Pharmaceuticals, sharing profits and losses at a 40% to 60% split. This customer concentration adds a layer of risk to the business since the company maintains limited internal commercial infrastructure and relies on the global footprint of its partner.
Source
Originally published at www.fool.com.